Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis.
Nanna Thurmann JørgensenTrine Møller ErichsenMorten Buus JørgensenThomas IdornBo Feldt-RasmussenJens J HolstUlla Feldt-RasmussenMarianne KlosePublished in: Pituitary (2023)
SSA impaired the insulin, glucagon, and incretin hormone secretions. Co-treatment with PEG seemed to counteract the somatostatinergic inhibition of the glucagon and insulin response to OGTT. We speculate that PEG may exert its action through GH-receptors on pancreatic δ-cells. Clinical trial registration NCT02005978.